

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

## Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation

### **This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1718183> since 2019-12-03T15:03:28Z

*Published version:*

DOI:10.1097/QAD.0000000000002442

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 **Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and**  
2 **Inflammation**

3 *Lupia T<sup>1#</sup>, Milia MG<sup>2</sup>, Atzori C<sup>3</sup>, Gianella S<sup>4</sup>, Audagnotto S<sup>1</sup>, Imperiale D<sup>3</sup>, Mighetto L<sup>5</sup>,*  
4 *Pirriatore V<sup>1</sup>, Gregori G<sup>2</sup>, Lipani F<sup>1</sup>, Ghisetti V<sup>2</sup>, Bonora S<sup>1</sup>, Di Perri G<sup>1</sup>, Calcagno A<sup>1</sup>.*

5 *1 Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino,*  
6 *Italy*

7 *2 Laboratory of Virology and Molecular Biology, Ospedale Amedeo di Savoia, ASL "Città di*  
8 *Torino", Torino, Italy*

9 *3 Unit of Neurology, Ospedale Maria Vittoria, ASL "Città di Torino", Torino, Italy*

10 *4 University of California San Diego, La Jolla, California, USA*

11 *5 Laboratory of Immunology, Ospedale Maria Vittoria, ASL "Città di Torino", Torino, Italy.*

12

13

14 **Running Head:** EBV and HIV in CSF

15

16

17 #Address correspondence to Tommaso Lupia, [tommaso.lupia89@gmail.com](mailto:tommaso.lupia89@gmail.com)

18 \*Present address: Tommaso Lupia, Unit of Infectious Diseases, Department of Medical  
19 Sciences, University of Torino, Amedeo di Savoia Hospital, C.so Svizzera 164, 10149 Torino,  
20 Italy

21

22

23

24 **Type of article:** Original article

25

26 **Key words:** EBV; HIV; central nervous system; blood brain barrier; trafficking; biomarkers; S-  
27 100 beta.

28

29 **Word count:** Total 2092 (Abstract 250)

30

31 **Figures:** 1

32

33 **Tables:** 2

34

35

36 **Conflicts of Interest and Source of Funding:** AC has received honoraria from Abbvie, BMS,  
37 Gilead, Janssen-Cilag, MSD, Viiv and he is currently receiving research grants from BMS,  
38 Gilead and Viiv. GDP and SB have received honoraria from Abbvie, BMS, Gilead, Janssen-  
39 Cilag, MSD, Viiv. The remaining authors have no conflict of interest to declare.

40

41

42

43

44

45

46 **Abstract**

47

48 Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) can infect several cells, replicate in the  
49 central nervous system and affect blood-brain barrier (BBB) integrity. This study aimed to  
50 investigate whether cerebrospinal fluid (CSF) EBV or CMV DNA was associated with viral,  
51 inflammatory and neuronal damage biomarkers in people living with HIV (PLWH).

52 EBV, CMV DNA and HIV RNA were measured on CSF, through RT-PCR, from PLWHs  
53 undergoing lumbar punctures for clinical reasons (excluding oncho-haematological  
54 comorbidities). Immune-enzymatic assays evaluated BBB inflammation and damage. Patients  
55 were stratified according to plasma HIV RNA levels in viremic ( $\geq 50$  copies/mL) and aviremic  
56 ( $< 50$  copies/mL). We included 298 participants. Among 167 viremic patients, CSF EBV and  
57 CMV DNA were detectable in 42 (25.1%) and 10 (6.3%) participants; among 130 aviremic  
58 subjects CSF EBV and CMV DNA were detectable in 12 (9.2%) and 0 (0%) participants,  
59 respectively. In viremic group, detectable CSF EBV DNA was associated with CSF pleocytosis  
60 ( $p < 0.001$ ), higher CSF HIV RNA ( $p < 0.001$ ) and neopterin levels ( $p = 0.002$ ). In aviremic  
61 participants, detectable EBV DNA was associated with pleocytosis ( $p = 0.056$ ), higher neopterin  
62 ( $p = 0.027$ ) and immune globulins ( $p = 0.016$ ) in the CSF; CSF escape was more common in those  
63 with detectable EBV DNA (50% vs. 21.2%,  $p = 0.036$ ).

64 EBV DNA was frequently detected in the CSF of viremic and fewer aviremic patients on  
65 antiretroviral treatment. In PLWH without clinical evidence of encephalitis CSF EBV DNA was  
66 associated with higher levels of HIV RNA and biomarkers of neuronal damage/inflammation.  
67 The role of EBV reactivation in HIV-associated CNS disorders warrants further studies.

68

ha eliminato:

ha eliminato: The aim of this study was

ha eliminato: We examined CSF samples participants undergoing lumbar punctures for clinical reasons (excluding those with lymphoproliferative disorders): we measured EBV, CMV DNA and HIV RNA (by PCR), markers of neuronal damage and inflammation (by immune-enzymatic assays).

ha eliminato: (with plasma HIV RNA  $< 50$  copies/mL)

ha eliminato: 131

ha eliminato:

ha eliminato: PLWH

ha eliminato:

ha eliminato:

ha eliminato: higher

ha eliminato: values

ha eliminato:  $<$

ha eliminato: ,

ha eliminato: participants

ha eliminato:  $<$

ha eliminato: 4

ha eliminato:  $<$

ha eliminato: 8

ha eliminato:  $<$

ha eliminato: 34

ha eliminato:

ha eliminato: ( $p$  values  $< 0.05$ )

ha eliminato: .

ha eliminato: 5

ha eliminato: EBV DNA was frequently detected at low levels in the CSF of viremic participants and in a minority of aviremic patients on antiretroviral treatment.

101 **Background:**

102 The central nervous system (CNS) is a clinically relevant target of HIV and severe forms of  
103 encephalitis and dementia have been described since the beginning of the epidemics [1]. Even  
104 in the current era of antiretroviral therapy (ART), chronic CNS involvement is a significant issue  
105 for people living with HIV (PLWH) [2]. In fact, HIV persists in the brain tissue of people living  
106 with HIV (PLWH) despite systemic viral control and its detection in the cerebrospinal fluid (CSF)  
107 has been associated with acute/subacute neurological symptoms, worse neurocognitive  
108 performances and immune activation [3]. While the clinical relevance of HIV RNA escape within  
109 the CSF is controversial, symptomatic cases have been described and ART optimizations have  
110 led to clinical/radiological/virologic improvements, thus supporting a pathogenetic role of HIV  
111 RNA active replication in the CNS [4]. The factors associated with HIV RNA escape in the CSF  
112 are poorly understood with several identified risk factors, such as low nadir CD4 cell count,  
113 dementia, poor adherence to ART, low level viremia in blood plasma and the presence of drug  
114 resistance associated mutations [5-6]. Another possible driver of compartmentalized HIV RNA  
115 replication in the CSF might be co-infection with other chronic viruses (“secondary escape”) but  
116 this has not been systematically investigated [7].

117 As part of this study, we focused on the effects of [Cytomegalovirus \(CMV\)](#) and Epstein-Barr  
118 virus (EBV) since PLWH have a higher risk of acquiring and incompletely controlling both  
119 viruses; both EBV [8-10] and CMV [11-13] have been associated with neurological disorders  
120 as well as vascular inflammation, thus suggesting the potential for chronic CNS and endothelial  
121 involvement (well recognized for CMV) [11-13]. In particular, EBV can infect macrovascular  
122 endothelial cells in human tissue [14-17], human brain micro-vessels [18] and human umbilical  
123 vein endothelial cells [19]. Endothelial cells with lytic reactivation of EBV present increase

ha eliminato: ¶



ha eliminato: c

129 production of pro- inflammatory molecules (CCL-2 and CCL-5) and also hyper-expression of  
130 surface adhesion molecules (ICAM-1 and VCAM-1) with a potential creation of an inflammatory  
131 breach through the Blood Brain Barrier (BBB) [12, 20-21]. This may be relevant because a key  
132 factor in chronic HIV RNA CNS involvement seems to be the alteration of the BBB: the latter  
133 has been recently described as being part of the neurovascular unit where endothelial cells  
134 (and pericytes) co-operate with astrocytes and neurons [22]. Thus, CMV and EBV may  
135 potentially cause a sub-clinical chronic infection and facilitate inflammatory cells' trafficking  
136 through the BBB increasing migration of HIV into the CNS. [7, 15, 23]

137

## 138 **Material and Methods**

### 139 **Cohort and Samples**

140 We enrolled adult PLWH undergoing lumbar punctures for clinical reasons, [in a cross-sectional](#)  
141 [design study](#), including late presentation with <100 CD4<sup>+</sup> T lymphocytes/mm<sup>3</sup> [in peripheral](#)  
142 [blood](#), opportunistic infections, new or persistent neurological symptoms (including headache),  
143 worsening cognitive impairment, need of lumbar puncture in case of syphilis or white matter  
144 hyperintensities at brain MRI. Patients with primary central nervous system lymphomas,  
145 lymphoproliferative diseases and autoimmune disorders were excluded from this study. [We](#)  
146 [also excluded HIV controllers without ART.](#) Demographic, immunovirological, clinical and  
147 therapeutic data were recorded as well as CSF characteristics. The protocol was approved by  
148 our Ethics Committee (Comitato Etico Inter-aziendale di Orbassano, n. 103/2015). Study  
149 participants signed a written informed consent at enrollment.

### 150 **Viral Measures**

ha eliminato: a

152 Levels of HIV RNA were measured by real time Polymerase Chain Reaction (RT-PCR) assay  
153 CAP/CTM HIV-1 vs. 2.0 (CAP/CTM, Roche Molecular System, Branchburg, NJ, HIV RNA  
154 detection limit: 20 copies/mL). Levels of EBV DNA and CMV DNA were measured through the  
155 RT-PCR (detection limit: 100 copies/mL). CSF escape was defined as CSF HIV RNA >50  
156 copies/mL with plasma HIV RNA <50 copies/mL and CSF/plasma discordance as CSF HIV  
157 RNA 0.5 Log<sub>10</sub> higher than plasma HIV RNA (if both were detectable) [24].

#### 158 **Immunological Measures and BBB Damage**

159 Quantitative determination of albumin in serum and CSF was measured by  
160 Immunoturbidimetric methods (AU 5800, Beckman Coulter, Brea, CA, USA). CSF to serum  
161 albumin ratio (CSAR) was calculated as albumin in CSF (mg/L)/albumin in serum (g/L), and  
162 was used to evaluate BBB permeability. Impaired BBB was defined according to age-adjusted  
163 Reibergrams (normal if below 6.5 in patients aged <40 years and below 8 in patients >40 years)  
164 [25]. The presence of Immune globulins (Ig)G produced inside the CNS was calculated  
165 according to Tibbling index [26]. CSF pleocytosis was defined as  $\geq 5$  cells/mm<sup>3</sup>.

166 CSF total tau (t-tau), phosphorylated tau (p-tau) and 1-42  $\beta$ -amyloid (A $\beta$ <sup>1-42</sup>) were measured by  
167 immunoenzymatic methods (Fujirebio diagnostics, Malvern, U.S.A.) with limits of detection of  
168 57, 20 and 225 pg/ml, respectively. Neopterin and S100B were measured through ELISA [DRG  
169 Diagnostics (Marburg, Germany) and DIAMETRA S.r.l. (Spello, Italy), respectively]. Upper  
170 limits of normality in HIV-negative individuals were as follows: t-tau [ $<300$  pg/mL (in participants  
171 aged 21–50),  $<450$  pg/mL (in participants aged 51–70) or  $<500$  pg/mL in older participants], p-  
172 tau ( $<61$  pg/mL), 1–42 beta amyloid ( $>500$  pg/mL), neopterin ( $<1.5$  ng/mL) and S100B ( $<380$   
173 pg/mL) [27].

174

## 175 **Statistical Analysis**

176 We performed descriptive statistics on the entire study population and then stratified between  
177 study participants with suppressed plasma HIV RNA (<50 copies/mL) and those with detectable  
178 HIV RNA.

179 Data were analyzed using standard statistical methods: variables were described with medians  
180 [interquartile ranges (IQR)], groups were compared using non-parametric tests (Mann–Whitney,  
181 Kruskal-Wallis and Spearman’s tests as specified in the text). Linear logistic regressions were  
182 used for estimating the association between detectable EBV/CMV DNA, HIV RNA, as well as  
183 biomarker of CNS damage and inflammation. Models were adjusted for CD4<sup>+</sup> cell counts and  
184 CSF HIV RNA. Data analysis was performed using PASW software version 22.0 (IBM).

185

## 186 **Results**

187 Two hundred and ninety-seven PLWH were included in this study, of whom 118 (39.4%) were  
188 naïve for ART. Baseline and immune-virological characteristics, stratified by plasma HIV RNA  
189 (below or above 50 copies/mL) are shown in **Table 1**.

190 EBV DNA was detected in the CSF of 42 (25.1%) and 12 (9.2%) participants with detectable  
191 and undetectable HIV RNA in plasma, respectively (p<0.001). Similarly, higher levels of EBV  
192 DNA were observed in the CSF of participants with detectable plasma HIV RNA (152 vs. <100  
193 copies/mL, p<0.001). Virological, neuronal damage and inflammation biomarkers stratified by  
194 plasma HIV RNA and CSF EBV DNA detection are shown in **Table 2**.

ha eliminato: eight

ha eliminato: 6

**ha spostato in basso [1]:** CMV DNA was detected only in the CSF of participants with plasma HIV RNA >50 copies/mL [10 (6.3%) vs. 0 (0%), p=0.006]; participants with detectable CSF CMV DNA presented lower CD4<sup>+</sup> T lymphocytes (25 vs. 91/mm<sup>3</sup>; p=0.005), higher plasma and CSF HIV RNA (5.8 vs. 5.1 Log<sub>10</sub> copies/mL, p=0.039 and 5.0 vs. 3.6 Log<sub>10</sub> copies/mL, p=0.016), higher CSAR (9.0 vs. 5.6, p=0.046) and neopterin (5.4 vs. 2.2 ng/mL, p=0.012) and they were more often diagnosed with opportunistic infections (40% vs. 17.3%, p=0.093).<sup>1</sup>



208 CMV DNA was detected only in the CSF of participants with plasma HIV RNA >50 copies/mL  
209 [10 (6.3%) vs. 0 (0%), p=0.006]; participants with detectable CSF CMV DNA had lower CD4<sup>+</sup> T  
210 lymphocytes (25 vs. 91/mm<sup>3</sup>, p=0.005), higher plasma and CSF HIV RNA (5.8 vs. 5.1 Log<sub>10</sub>  
211 copies/mL, p=0.039 and 5.0 vs. 3.6 Log<sub>10</sub> copies/mL, p=0.016), higher CSAR (9.0 vs. 5.6,  
212 p=0.046) and neopterin (5.4 vs. 2.2 ng/mL, p=0.012) and they were more often diagnosed with  
213 opportunistic infections (40% vs. 17.3%, p=0.093).

ha spostato (inserimento) [1]

ha eliminato: presented lowed

214  
215 In PLWH with detectable plasma HIV RNA, presence of detectable EBV DNA was associated  
216 with a significantly higher number of cells, greater CSAR, as well as increased HIV RNA and  
217 neopterin in the CSF. In participants with plasma HIV RNA <50 copies/mL, presence of  
218 detectable EBV DNA was associated with significantly higher number of cells and greater  
219 neopterin in the CSF. The presence of IgG produced within the CNS was more common in  
220 aviremic participants with detectable CSF EBV DNA (38% vs. 0%, p=0.036). Additionally, CSF  
221 HIV RNA escape was more common in ART-suppressed participants with detectable EBV DNA  
222 (50% vs. 21%, p=0.036) (Figure 1).

ha eliminato: 4

ha eliminato: 5

223 No correlation was observed between EBV DNA concentrations and the studied biomarkers.

224 Linear logistic analysis (adjusted for CD4 cell count and CSF HIV RNA) suggested that a  
225 detectable EBV DNA was independently associated with CSF pleocytosis in PLWH with CSF  
226 HIV RNA <50 copies/mL (p<0.001) and non-controllers (p<0.001), with neopterin in HIV non-  
227 controllers (p=0.015) and with the production of IgG within the CNS in HIV-controllers (p=0.008).

228

232

233 **Discussion**

234 To better understand the role of EBV and CMV in the CNS on HIV RNA replication, BBB  
235 damage and biomarkers of neuronal damage/inflammation, we measured levels of CMV and  
236 EBV DNA in CSF of 298 PLWH.

237 Overall, we observed that EBV DNA was detectable at low levels in 18% of all PLWH and it  
238 was associated with higher levels of HIV RNA in the CSF and up to three-time higher rate of  
239 pleocytosis. Compared to viremic subjects (25.1%), EBV DNA was found less frequently in  
240 study participants with undetectable HIV RNA in plasma (9.2%), and its presence was  
241 associated with pleocytosis, IgG production within the CNS and presence of CSF HIV RNA  
242 escape. CMV DNA, on the contrary, was found only in HIV viremic participants and was  
243 associated with low CD4<sup>+</sup> cell count, high plasma HIV RNA and opportunistic disorders.

244 Our findings are similar to those reported by Weinberg et al. in HIV-negative individuals where  
245 the presence of pleocytosis was associated with detectable CSF EBV DNA but also presence  
246 of EBV related-mRNA, supporting the hypothesis that EBV DNA is not just carried by latently  
247 infected inflammatory cells (e.g. B cells) but the consequence of actively replicating virus [28].  
248 Furthermore, EBV affects the immune system and it may enhance neuronal degeneration in  
249 chronic inflammatory conditions [29-30]. Our data are in line with this hypothesis since both  
250 viremic and ART-suppressed PLWH [showed](#) higher CSF HIV RNA levels (and CSF to plasma  
251 HIV RNA ratios) and increased white blood cells when EBV DNA was detectable. Additionally,  
252 PLWH with detectable HIV RNA and EBV DNA in CSF also showed higher CSAR supporting  
253 a potential role of chronic EBV infection in BBB damage, which in turn is associated with

ha eliminato: presented

255 neurocognitive impairment, and with neuronal damage and inflammation [31-33]. In vitro  
256 experiments suggest that hosting EBV astrocytes and microglia may enhance cell-to-cell  
257 crosstalk and favoring migration of monocytic/macrophagic line cells into the CNS [34-36]. This  
258 effect may be independent from HIV control and immune system improvement: these conditions  
259 have been associated with the absence of neuronal damage and with the lowest CSF  
260 concentrations of neopterin [37-39].

261 Despite the low level or absent plasmatic EBV and CMV replication can be found at higher  
262 concentrations in tissues and organs. In a recent study that analyzed 108 gut biopsies collected  
263 from 19 HIV-infected and 22 HIV-uninfected participants, CMV and EBV were detected in more  
264 than 70% of samples but more commonly in HIV-positive subjects [40]. While the negative  
265 effects of sporadic or continuous CMV replication are well-known, there is still uncertainty on  
266 the role of EBV in favoring chronic immune activation. Neuroinflammation, neurodegeneration  
267 and its drivers are widely studied in MS and Late EBV infection seemed to be one of the risk  
268 factors involved in promoting the initial events and the relapses of this chronic neurological  
269 condition [41-42]. In most CSF of MS patients were founded elevated antibody levels against  
270 the entire EBV nuclear antigen (EBNA), and EBNA-1, a protein expressed during latent EBV-  
271 infection [43-44]. Anti-EBNA-1 IgG antibodies were correlated also with CSF oligoclonal bands  
272 and in some patients oligoclonal bands include anti-EBV antibodies [45]. Reactivation of EBV  
273 in the central nervous system (CNS) has been proposed as a possible cause of MS although  
274 the virus has not been consistently found in MS lesions [41].

275 From a broader perspective the lifelong presence of most Herpesviridae in the organism may  
276 produce in some hosts alterations in neuronal cellular processes [46-47]. These observations  
277 were suggested by several studies suggesting an association between EBV, human

ha eliminato: replication

279 herpesvirus-1 and 6 (HSV-1 and HHV-6) with Alzheimer's (AD) and other neurodegenerative  
280 diseases [48-50]. Very recently HHV-6A and HHV-7 produced disruption of molecular, genetic,  
281 and clinical networks was reported in autaptic brains from patients suffering of AD along with  
282 [51-52].

283 Additionally, EBV may play a role in suppressing the CNS immune system and therefore  
284 maintain an incomplete T-cell mediated inflammatory response, through the expression of viral  
285 genes encoding for proteins with immunoevasion-like function. This may translate into higher  
286 rates of pleocytosis but with less inflammatory activity [53-54]. On the other hand, ART-  
287 suppressed study participants with detectable EBV DNA showed lower CD4<sup>+</sup> T cell counts thus  
288 suggesting that immune control may be needed in order to restore a partial control on EBV  
289 replication.

290 CMV DNA was detected in naïve patients only and, specifically, in patients presenting with  
291 advanced immune depletion and opportunistic infections and with high viral replication both in  
292 plasma and CSF. Additionally, BBB damage and monocyte-derived inflammation were  
293 significantly higher in participants with detectable CSF CMV DNA. Further speculations on the  
294 role of CMV are limited by the low number of participants in this subgroup; yet it may be peculiar  
295 of individuals with very severe immunodeficit and, as already shown by several reports, at  
296 higher risk of poor survival. [55,56]

297 Some limitations of this study should be acknowledged including the low sample size, the cross-  
298 sectional design, the lack of a control group and the lack of plasma EBV DNA measurements.  
299 We also did not collect neurocognitive data in all participants. Importantly, in this observational  
300 study we cannot assess the causal relationship between presence of EBV, inflammation and  
301 HIV RNA escape. Additionally, our cohorts include several patients with very low nadir CD4<sup>+</sup> T

302 cell counts and heterogeneous clinical conditions: the same effect may not be observed in  
303 individuals with less advanced disease.

304 In conclusion we reported for the first time the presence of detectable EBV DNA in the CSF of  
305 PLWH without lympho-proliferative disorders and with no evidence of viral encephalitis. We  
306 observed that ART-naïve subjects with detectable EBV DNA in the CSF had a higher HIV RNA  
307 viral load and also higher markers of neuronal damage and inflammation; Similarly, in ART-  
308 suppressed individuals we observed increased HIV RNA and also evidence of BBB damage,  
309 greater pleocytosis and immune activation. Further studies are warranted for understanding the  
310 contribution of EBV to HIV-associated CNS disorders.

311

## 312 **References**

- 313 1. Zayyad, Z., & Spudich, S. (2015). Neuropathogenesis of HIV: From Initial  
314 Neuroinvasion to HIV-Associated Neurocognitive Disorder (HAND). *Current HIV/AIDS*  
315 *Reports*, 12(1), 16–24. <https://doi.org/10.1007/s11904-014-0255-3>
- 316 2. Thakur, K. T., Boubour, A., Saylor, D., Das, M., Bearden, D. R., & Birbeck, G. L. (2019).  
317 *Global HIV neurology: a comprehensive review. AIDS (London, England)* (Vol. 33).  
318 <https://doi.org/10.1097/QAD.0000000000001796>
- 319 3. Rosenthal, J., & Tyor, W. (2019). Aging, comorbidities, and the importance of finding  
320 biomarkers for HIV-associated neurocognitive disorders. *Journal of NeuroVirology*.  
321 <https://doi.org/10.1007/s13365-019-00735-0>
- 322 4. Nightingale, S., Geretti, A. M., Beloukas, A., Fisher, M., Winston, A., Else, L., ... Khoo,  
323 S. (2016). Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level

- 324 viraemia. *Journal of NeuroVirology*, 22(6), 852–860. [https://doi.org/10.1007/s13365-](https://doi.org/10.1007/s13365-016-0448-1)  
325 016-0448-1
- 326 5. Eggers, C., Arendt, G., Hahn, K., Husstedt, I. W., Maschke, M., Straube, E. (2017).  
327 HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and  
328 treatment. *Journal of Neurology*, 264(8), 1715–1727. [https://doi.org/10.1007/s00415-](https://doi.org/10.1007/s00415-017-8503-2)  
329 017-8503-2
- 330 6. Pérez-Valero, I., Ellis, R., Heaton, R., Deutsch, R., Franklin, D., Clifford, D. B.,  
331 Letendre, S. (2019). Cerebrospinal fluid viral escape in aviremic HIV-infected patients  
332 receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.  
333 *AIDS (London, England)*, 33(3), 475–481.  
334 <https://doi.org/10.1097/QAD.0000000000002074>
- 335 7. Ferretti F., Gisslen M., Cinque P., Price RW: Cerebrospinal Fluid HIV Escape from  
336 Antiretroviral Therapy *Curr HIV/AIDS Rep* (2015) 12:280–288
- 337 8. Corcoran C, Rebe K, van der Plas H, Myer L, Hardie DR. The predictive value of  
338 cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous  
339 system lymphoma in HIV-infected persons. *J Clin Virol* 2008; **42**: 433-436. [Medline](#)  
340 [doi:10.1016/j.jcv.2008.03.017](https://doi.org/10.1016/j.jcv.2008.03.017)
- 341 9. Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of  
342 cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-  
343 related primary central nervous system lymphoma. *Clin Infect Dis* 2004; **38**: 1629-1632.  
344 [Medline](#) [doi:10.1086/420934](https://doi.org/10.1086/420934)
- 345 10. Wang J, Ozzard A, Nathan M, *et al*. The significance of Epstein-Barr virus detected in  
346 the cerebrospinal fluid of people with HIV infection. *HIV Med* 2007; **8**: 306-311. [Medline](#)  
347 [doi:10.1111/j.1468-1293.2007.00475.x](https://doi.org/10.1111/j.1468-1293.2007.00475.x)

- 348 11. Cinque, P., L. Vago, M. Brytting, A. Castagna, A. Accordini, V.-A. Sunqvist, N.  
349 Zanchetta, A. D'Arminio Monforte, B. Wahren, A. Lazzarin, and A. Linde. 1992.  
350 Cytomegalovirus infection of the central nervous system in patients with AIDS:  
351 diagnosis by DNA amplification from cerebrospinal fluid. *J. Infect. Dis.* 166:1408–1411.
- 352 12. Cinque, P., G. M. Cleator, T. Weber, P. Monteyne, C. Sindic, G. Gerna, A. Van Loon,  
353 and P. E. Klapper for the European Union Concerted Action on Virus Meningitis and  
354 Encephalitis. 1998. Diagnosis and clinical management of neurological disorders  
355 caused by cytomegalovirus in AIDS patients. *J. Neurovirol.* 4:120–132.
- 356 13. Clifford, D. B., R. S. Buller, S. Mohammed, L. Robinson, and G. A. Storch. 1993. Use of  
357 polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with  
358 human immunodeficiency virus infection. *Neurology* 43:75–79.
- 359 14. Kobayashi Z, Tsuchiya K, Takahashi M et al. An autopsy case of chronic active  
360 Epstein–Barr virus infection (CAEBV): Distribution of central nervous system (CNS)  
361 lesions. *JNeuroSci*2008; 275:170–7
- 362 15. Jha HC, Mehta D, Lu J, El-Naccache D, Shukla SK, Kovacsics C, Kolson D, Robertson  
363 ES. 2016. Gammaherpesvirus infection of human neuronal cells. *mBio* 6(6):e01844-15.  
364 doi:10.1128/mBio.01844-15
- 365 16. Kano K.,Katayama T., Takeguchi S., Asanome A.,Takahashi K., Saito T.,Sawada J.,  
366 Saito M., Biopsy-proven case of Epstein–Barr virus (EBV)-associated vasculitis of the  
367 central nervous system, *Neuropathology* 2017; 37,259–264
- 368 17. Casiraghi C, Dorovini-Zis K, Epstein-Barr virus infection of human brain microvessel  
369 endothelial cells: A novel role in multiple sclerosis, *Journal of Neuroimmunology* 2011 ,  
370 Volume 230 , Issue 1 , 173 – 177

- 371 18. Jones K., Rivera C., Sgadari C., Franklin J., Max E.E., Bhatia K., Tosato G. Infection of  
372 human endothelial cells with Epstein-Barr virus. *J. Exp. Med.* 1995;182:1213–1221
- 373 19. Xiong A, Clarke-Katzenberg RH, Valenzuela G, Izumi KM, Millan MT. Epstein-Barr virus  
374 latent membrane protein 1 activates nuclear factor- $\kappa$ B in human endothelial cells and  
375 inhibits apoptosis. *Transplantation.* 2004;78:41–9
- 376 20. Kanno H, Watabe D, Shimazu N et al. Adhesion of Epstein–Barr virus-positive natural  
377 killer cell lines to cultured endothelial cells stimulated with inflammatory cytokines. *Clin*  
378 *Exp Immunol* 2008; 151:519
- 379 21. Houldcroft CJ, Kellam P., Host genetics of Epstein–Barr virus infection, latency and  
380 disease, *Rev. Med. Virol.* 2015; 25: 71–84
- 381 22. Muoio, V., Persson, P. B., & Sendeski, M. M. (2014). The neurovascular unit - concept  
382 review. *Acta Physiologica*, 210(4), 790–798. <https://doi.org/10.1111/apha.12250>
- 383 23. Hutt-Fletcher LM. Epstein–Barr virus entry. *Journal of Virology* 2007; 81: 7825–7832
- 384 24. Trunfio M, Pinnetti C, Focà E et al., Cerebrospinal fluid HIV-1 escape according to  
385 different thresholds and underlying comorbidities: is it time to assess the definitions?,  
386 *AIDS.* 2019 Mar 15;33(4):759-762. doi: 10.1097/QAD.0000000000002091.
- 387 25. Reiber, H., Lange, P., 1991. Quantification of virus-specific antibodies in cerebrospinal  
388 fluid and serum: sensitive and specific detection of antibody synthesis in brain. *Clin.*  
389 *Chem.* 37 (7), 1153–1160.G.
- 390 26. Tibbling, H. Link & S. Öhman (1977) Principles of albumin and IgG analyses in  
391 neurological disorders. I. Establishment of reference values, *Scandinavian Journal of*  
392 *Clinical and Laboratory Investigation*, 37:5, 385-390, DOI:  
393 [10.1080/00365517709091496](https://doi.org/10.1080/00365517709091496)



- 394 27. Green AJ, Harvey RJ, Thompson EJ, Rossor MN (1997) Increased S100beta in the  
395 cerebrospinal fluid of patients with frontotemporal dementia. *Neurosci Lett* 235(1-2):5–8
- 396 28. Weinberg A. , Shaobing L., Palmer M., et al: Quantitative CSF PCR in Epstein-Barr  
397 virus infection of the central nervous system. *Ann Neurol* 2002;52:543—548
- 398 29. Wang J, Ozzard A, Nathan M, Atkins M, Nelson M, Gazzard B, Bower M 2007. The  
399 significance of Epstein-Barr virus detected in the cerebrospinal fluid of people with HIV  
400 infection. *HIV Med* 8:306–311
- 401 30. Xu S., Gaskin F., Increased incidence of anti-b-amyloid autoantibodies secreted by  
402 Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease  
403 *Mechanisms of Ageing and Development*, 94 (1997) 213–222
- 404 31. Calcagno A, Atzori C, Romito A et al (2016) Blood brain barrier impairment is  
405 associated with cerebrospinal fluid markers of neuronal damage in HIV-positive  
406 patients. *J Neurovirol* 22(1):88–92
- 407 32. Anesten B, Yilmaz A, Hagberg L, et al. : Blood-brain barrier integrity, intrathecal  
408 immunoactivation, and neuronal injury in HIV. *Neurol Neuroimmunol Neuroinflamm.*  
409 2016;3(6):e300
- 410 33. Carroll A, Brew B. HIV-associated neurocognitive disorders: recent advances in  
411 pathogenesis, biomarkers, and treatment. *F1000Res* 2017; 6:312
- 412 34. A. Menet, C. Speth, C. Larcher, W. M. Prodinger, M. G. Schwendinger, P. C. et al.  
413 (1999). Epstein-Barr Virus Infection of Human Astrocyte Cell Lines. *Journal of Virology*,  
414 73(9), 7722–7733.

- 415 35. Daugvilaite, V., Arfelt, K. N., Benned-Jensen, T., Sailer, A. W., & Rosenkilde, M. M.  
416 (2014). Oxysterol-EBI2 signaling in immune regulation and viral infection. *European*  
417 *Journal of Immunology*, 44(7), 1904–1912. <https://doi.org/10.1002/eji.201444493>
- 418 36. Rutkowska, A., Preuss, I., Gessier, F., Sailer, A. W., & Dev, K. K. (2015). EBI2  
419 regulates intracellular signaling and migration in human astrocyte. *Glia*, 63(2), 341–351.  
420 <https://doi.org/10.1002/glia.22757>
- 421 37. Dahl V, Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years  
422 of suppressive therapy are associated with local immune activation. *AIDS*.  
423 2014;28:2251–2258
- 424 38. Chan P, Hellmuth J, Spudich S, Valcour V (2016) Cognitive impairment and persistent  
425 CNS injury in treated HIV. *Curr HIV/AIDS Rep* 13:209–217
- 426 39. Motta I., Alice T., Romito A., Calcagno A.: Cerebrospinal fluid viral load and neopterin in  
427 HIV-positive patients with undetectable viraemia., *Antivir Ther* 2017 Feb 15
- 428 40. Gianella S., Chaillon MA, Mutlu EA. : Effect of cytomegalovirus and Epstein–Barr virus  
429 replication on intestinal mucosal gene expression and microbiome composition of HIV-  
430 infected and uninfected individuals, *AIDS* 2017, 31:2059–2067
- 431 41. Laurence, M., & Benito-León, J. (2017). Epstein–Barr virus and multiple sclerosis:  
432 Updating Pender’s hypothesis. *Multiple Sclerosis and Related Disorders*, 16(May), 8–  
433 14. <https://doi.org/10.1016/j.msard.2017.05.009>
- 434 42. Sisay, S., Lopez-Lozano, L., Mickunas, M., Quiroga-Fernández, A., Palace, J., Warnes,  
435 G., ... Meier, U. C. (2017). Untreated relapsing remitting multiple sclerosis patients  
436 show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the  
437 periphery and innate immune IL-8 responses preferentially in the CNS. *Journal of*  
438 *Neuroimmunology*, 306, 40–45. <https://doi.org/10.1016/j.jneuroim.2017.02.017>

- 439 43. Munger, K.L., Levin, L.I., O'Reilly, E.J., Falk, K.I., Ascherio, A., 2011. Anti-Epstein-Barr  
440 virus antibodies as serological markers of multiple sclerosis: a prospective study among  
441 United States military personnel. *Mult. Scler.* 17 (10), 1185–1193.
- 442 44. Kuhle, J., Disanto, G., Dobson, R., Adutori, R., Bianchi, L., Topping, J., et al., 2015.  
443 Conversion from clinically isolated syndrome to multiple sclerosis: a large multicenter  
444 study. *Mult. Scler.* 21 (8), 1013–1024.
- 445 45. Virtanen, J.O., Wohler, J., Fenton, K., Reich, D.S., Jacobson, S., 2014. Oligoclonal  
446 bands in multiple sclerosis reactive against two herpesviruses and association with  
447 magnetic resonance imaging findings. *Mult. Scler.* 20 (1), 27–34.
- 448 46. Dobson, C. B., Wozniak, M. A., and Itzhaki, R. F. (2003). Do infectious agents play a  
449 role in dementia? *Trends Microbiol.* 11, 312–317. doi: 10.1016/s0966842x(03)00146-x
- 450 47. Buscarinu, M. C., Fornasiero, A., Romano, S., Ferraldeschi, M., Renié, R., Trasimeni,  
451 G., et al. (2017). Coincident onset of multiple sclerosis and Herpes simplex virus 1  
452 encephalitis: a case report. *Mult. Scler. Demyelinating Disord.* 2:6. doi:  
453 10.1186/s40893-017-0023-5
- 454 48. Casiraghi, C., Citlali Márquez, A., Shanina, I., and Horwitz, M. S. (2015). Latent virus  
455 infection upregulates CD40 expression facilitating enhanced autoimmunity in a model of  
456 multiple sclerosis. *Sci. Rep.* 5:13995. doi: 10.1038/srep13995
- 457 49. Casiraghi, C., Shanina, I., Cho, S., Freeman, M. L., Blackman, M. A., and Horwitz, M.  
458 S. (2012).  $\gamma$ herpesvirus latency accentuates EAE pathogenesis: relevance to epstein-  
459 barr virus and multiple sclerosis. *PLoS Pathog.* 8:e1002715. doi:  
460 10.1371/journal.ppat.1002715
- 461 50. Leibovitch, E. C., Caruso, B., Kwon, S., Schindler, M. K., Lee, N. J., Luciano, N. J., et  
462 al. (2018). Herpesvirus trigger accelerates neuroinflammation in a nonhuman primate

- 463 model of multiple sclerosis. *Proc. Natl. Acad. Sci. U S A* 115, 11292–11297. doi:  
464 10.1073/pnas.1811974115
- 465 51. Readhead, B. et al. (2018) Multiscale analysis of independent Alzheimer's cohorts finds  
466 disruption of molecular, genetic, and clinical networks by human herpesvirus. *Neuron*  
467 99, 64 – 82.e7
- 468 52. Eimer, W.A. et al. (2018) Alzheimer's disease-associated beta-amyloid is rapidly  
469 seeded by herpesviridae to protect against brain infection. *Neuron* 99, 56 – 63.e3
- 470 53. Tagawa T, et al. (2016) Epstein-Barr viral miRNAs inhibit antiviral CD4+ T-cell  
471 responses targeting IL-12 and peptide processing. *J Exp Med*, 10.1084/jem.2016024
- 472 54. Rensing, M.E., M. van Gent, A.M. Gram, M.J.G. Hooykaas, S.J. Piersma, and E.J.H.J.  
473 Wiertz. 2015. Immune evasion by Epstein-Barr virus. *Curr. Top. Microbiol. Immunol.*  
474 391:355–381.
- 475 55. El Amari EB, Combescure C, Yerly S, et al. Clinical relevance of cytomegalovirus  
476 viraemia. *HIV Med.* 2011;12(7):394-402.
- 477 56. Fielding K, Koba A, Grant AD, et al. Cytomegalovirus viremia as a risk factor for  
478 mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa.  
479 *PLoS One.* 2011;6(10):e25571.